首页> 外文期刊>Pharmacology: International Journal of Experimental and Clinical Pharmacology >Yokota, S.-I., Hikasa, Y., Mizushima, H.Effects of Imidazoline and Non-Imidazoline α-Adrenergic Agents on Rabbit Platelet Aggregation
【24h】

Yokota, S.-I., Hikasa, Y., Mizushima, H.Effects of Imidazoline and Non-Imidazoline α-Adrenergic Agents on Rabbit Platelet Aggregation

机译:Yokota,S.-I.,Hikasa,Y.,Mizushima,H.咪唑啉和非咪唑啉α-肾上腺素能药物对兔血小板聚集的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background/Aims: Imidazoline α2-adrenergic agents exert complex effects on mammalian platelet aggregation. Although non-adrenergic, imidazoline (I) receptors have been revealed in human platelets, there is limited information about imidazoline's action on platelet aggregation. This study aimed to investigate aggregatory and anti-aggregatory effects of various imidazoline or non-imidazoline α-adrenergic agents on rabbit platelets. Methods: Aggregatory responses of agents on rabbit platelets were examined by turbidimetric method. Radioligand binding assay to platelet I1 and I2 receptors was performed using [3H]-clonidine and [ 3H]-idazoxan, respectively. Results: Aggregation was not induced by α-adrenoceptor agonists alone. Adrenaline and noradrenaline produced dose-dependent potentiation of ADP- or collagen-induced aggregation. Imidazoline adrenoceptor agonists clonidine and p-aminoclonidine also potentiated ADP-induced platelet aggregation. The α2-adrenoceptor antagonists and/or certain imidazoline adrenergic agents inhibited adrenaline-potentiated aggregation in a dose-dependent manner, whereas α1-adrenoceptor antagonists and non-imidazoline α-adrenergic agents were either ineffective or less effective in inhibiting adrenaline-potentiated aggregation. Rabbit platelets did not have I1 receptors, but had I2 receptors, indicating that adrenaline-potentiated platelet aggregation was inhibited by idazoxan, but not by imidazoline compounds clonidine and oxymetazoline. Conclusions/Implications: These results demonstrated that α2-adrenoceptor-blocking agents and/or imidazoline α-adrenergic agents effectively inhibit adrenaline-potentiated platelet aggregation. It is proposed that imidazoline structure in part plays a role in the inhibition of adrenaline-potentiated aggregation.
机译:背景/目的:咪唑啉α2-肾上腺素能药物对哺乳动物的血小板聚集具有复杂的作用。尽管在人的血小板中已经发现了非肾上腺素咪唑啉(I)受体,但是关于咪唑啉对血小板聚集作用的信息有限。这项研究旨在研究各种咪唑啉或非咪唑啉α-肾上腺素能对兔血小板的聚集和抗聚集作用。方法:采用比浊法检测药剂对兔血小板的聚集反应。分别使用[3H]-可乐定和[3H]-咪唑烷对血小板I1和I2受体进行放射性配体结合测定。结果:聚集不是单独由α-肾上腺素受体激动剂诱导的。肾上腺素和去甲肾上腺素产生剂量依赖性的ADP或胶原诱导的聚集增强。咪唑啉肾上腺素受体激动剂可乐定和对氨基可乐定也可增强ADP诱导的血小板凝集。 α2-肾上腺素能受体拮抗剂和/或某些咪唑啉肾上腺素能药物以剂量依赖的方式抑制肾上腺素增强的聚集,而α1-肾上腺素能受体拮抗剂和非咪唑啉α-肾上腺素药物在抑制肾上腺素增强的作用上无效或较不有效。兔血小板不具有I1受体,但具有I2受体,表明肾上腺素增强的血小板聚集被咪唑azo生抑制,但不被咪唑啉化合物可乐定和羟甲唑啉抑制。结论/意义:这些结果表明α2-肾上腺素受体阻断剂和/或咪唑啉α-肾上腺素能药物有效抑制肾上腺素增强的血小板凝集。提出咪唑啉结构部分在抑制肾上腺素增强的聚集中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号